The future of canine glaucoma therapy

András M. Komáromy, Dineli Bras, Douglas W. Esson, Ronald L. Fellman, Sinisa D. Grozdanic, Larry Kagemann, Paul E. Miller, Sayoko E. Moroi, Caryn E. Plummer, John S. Sapienza, Eric S. Storey, Leandro B. Teixeira, Carol B Toris, Terah R. Webb

Research output: Contribution to journalReview article

Abstract

Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO-VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP-lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

Original languageEnglish (US)
JournalVeterinary Ophthalmology
DOIs
StatePublished - Jan 1 2019

Fingerprint

glaucoma
Glaucoma
Canidae
therapeutics
dogs
Intraocular Pressure
Dogs
Therapeutics
research planning
Optic Nerve Diseases
research support
peripheral nervous system diseases
medical treatment
Cell- and Tissue-Based Therapy
optics
Research
drug therapy
stem cells
Early Diagnosis
Stem Cells

Keywords

  • aqueous humor
  • canine
  • glaucoma
  • intraocular pressure
  • optic nerve
  • surgery

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Komáromy, A. M., Bras, D., Esson, D. W., Fellman, R. L., Grozdanic, S. D., Kagemann, L., ... Webb, T. R. (2019). The future of canine glaucoma therapy. Veterinary Ophthalmology. https://doi.org/10.1111/vop.12678

The future of canine glaucoma therapy. / Komáromy, András M.; Bras, Dineli; Esson, Douglas W.; Fellman, Ronald L.; Grozdanic, Sinisa D.; Kagemann, Larry; Miller, Paul E.; Moroi, Sayoko E.; Plummer, Caryn E.; Sapienza, John S.; Storey, Eric S.; Teixeira, Leandro B.; Toris, Carol B; Webb, Terah R.

In: Veterinary Ophthalmology, 01.01.2019.

Research output: Contribution to journalReview article

Komáromy, AM, Bras, D, Esson, DW, Fellman, RL, Grozdanic, SD, Kagemann, L, Miller, PE, Moroi, SE, Plummer, CE, Sapienza, JS, Storey, ES, Teixeira, LB, Toris, CB & Webb, TR 2019, 'The future of canine glaucoma therapy', Veterinary Ophthalmology. https://doi.org/10.1111/vop.12678
Komáromy AM, Bras D, Esson DW, Fellman RL, Grozdanic SD, Kagemann L et al. The future of canine glaucoma therapy. Veterinary Ophthalmology. 2019 Jan 1. https://doi.org/10.1111/vop.12678
Komáromy, András M. ; Bras, Dineli ; Esson, Douglas W. ; Fellman, Ronald L. ; Grozdanic, Sinisa D. ; Kagemann, Larry ; Miller, Paul E. ; Moroi, Sayoko E. ; Plummer, Caryn E. ; Sapienza, John S. ; Storey, Eric S. ; Teixeira, Leandro B. ; Toris, Carol B ; Webb, Terah R. / The future of canine glaucoma therapy. In: Veterinary Ophthalmology. 2019.
@article{128fc553eb9849ce96ab3fb89a48e5eb,
title = "The future of canine glaucoma therapy",
abstract = "Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO-VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP-lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.",
keywords = "aqueous humor, canine, glaucoma, intraocular pressure, optic nerve, surgery",
author = "Kom{\'a}romy, {Andr{\'a}s M.} and Dineli Bras and Esson, {Douglas W.} and Fellman, {Ronald L.} and Grozdanic, {Sinisa D.} and Larry Kagemann and Miller, {Paul E.} and Moroi, {Sayoko E.} and Plummer, {Caryn E.} and Sapienza, {John S.} and Storey, {Eric S.} and Teixeira, {Leandro B.} and Toris, {Carol B} and Webb, {Terah R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/vop.12678",
language = "English (US)",
journal = "Veterinary Ophthalmology",
issn = "1463-5216",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The future of canine glaucoma therapy

AU - Komáromy, András M.

AU - Bras, Dineli

AU - Esson, Douglas W.

AU - Fellman, Ronald L.

AU - Grozdanic, Sinisa D.

AU - Kagemann, Larry

AU - Miller, Paul E.

AU - Moroi, Sayoko E.

AU - Plummer, Caryn E.

AU - Sapienza, John S.

AU - Storey, Eric S.

AU - Teixeira, Leandro B.

AU - Toris, Carol B

AU - Webb, Terah R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO-VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP-lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

AB - Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO-VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP-lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

KW - aqueous humor

KW - canine

KW - glaucoma

KW - intraocular pressure

KW - optic nerve

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85066100313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066100313&partnerID=8YFLogxK

U2 - 10.1111/vop.12678

DO - 10.1111/vop.12678

M3 - Review article

JO - Veterinary Ophthalmology

JF - Veterinary Ophthalmology

SN - 1463-5216

ER -